<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949312</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000649763</org_study_id>
    <secondary_id>UCLA-0809064</secondary_id>
    <secondary_id>BILA-UECC-0107</secondary_id>
    <secondary_id>IRB# 08-09-064-02</secondary_id>
    <nct_id>NCT00949312</nct_id>
  </id_info>
  <brief_title>Studying Lymph Nodes in Patients With Stage II Colon Cancer</brief_title>
  <official_title>Ultrastaging of Early Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>John Wayne Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures that look for micrometastases in lymph nodes removed during&#xD;
      surgery for colon cancer may help doctors learn the extent of disease.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying lymph nodes in patients with stage II colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether the immunohistochemical and molecular presence of micrometastases in ≥&#xD;
           12 lymph nodes removed during en-bloc resection in patients with stage II colon cancer&#xD;
           correlates with 3-year disease-free survival.&#xD;
&#xD;
        -  Evaluate the prognostic significance of molecular markers detected in the primary tumor&#xD;
           and develop a microarray-based gene signature for stage II colon cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Tumor tissue and regional lymph node samples are collected during surgery for analysis of&#xD;
      micrometastases and molecular markers by immunohistochemistry, qRT-PCR, MM qRT-PCR,&#xD;
      qRDNA-PCR, and microarray profiling.&#xD;
&#xD;
      Patients are followed up periodically for 4 years after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2009</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (time to local or distant recurrence after resection)</measure>
    <time_frame>48 months</time_frame>
    <description>The event to be used for DFS is time to recurrence (local or distant) after resection of colon cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (time to death from colorectal cancer)</measure>
    <time_frame>48 months</time_frame>
    <description>The event to be used for DFS is time to death after resection of colon cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA marker analysis of lymph node and primary tumors</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray profiling of primary tumors</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction of lymph node specimens</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory RNA and DNA biomarker analysis of primary tumors</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>regional lymph node dissection</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lymph node staining for H&amp;E and pancytokeratin IHC</intervention_name>
    <arm_group_label>Stage II unresected Colon Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paraffin-embedded primary tumor and lymph node sections&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        From the ambulatory cancer clinic, we will identify 300 stage II colon cancer patients&#xD;
        eligible for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: All of the following inclusion criteria must be met in order for the&#xD;
        subject to be eligible.&#xD;
&#xD;
          1. Subjects must have CC detected by proctosigmoidoscopy, flexible endoscopy, or&#xD;
             gastrograffin/barium enema, with no evidence of distant metastases within 8 weeks of&#xD;
             enrollment.&#xD;
&#xD;
          2. Subjects with CC must have a computerized tomography (CT; at a minimum - spiral&#xD;
             (helical) CT with 5-mm contiguous reconstruction algorithms and adequate volume (based&#xD;
             on site-specific protocols) of oral and intravenous contrast agents) of the abdomen&#xD;
             and pelvis and a chest x-ray or CT of the chest per standard of care, within 8 weeks&#xD;
             prior to enrollment to rule out distant metastases. Subjects with preoperative CT&#xD;
             scans and testing showing non-specific or non-diagnostic (equivocal) abnormalities may&#xD;
             be eligible pending intraoperative exploration.&#xD;
&#xD;
          3. Greater than 18 years of age&#xD;
&#xD;
          4. Subjects must have a performance status ≤ 2 on the ECOG/Zubrod scale.&#xD;
&#xD;
          5. Subject is able to give informed consent, and must be willing to be followed&#xD;
             clinically or by phone/email/mail correspondence&#xD;
&#xD;
          6. Subject must have a life expectancy of greater than 5 years not including the&#xD;
             disease/diagnosis of CC.&#xD;
&#xD;
          7. Subject must have clinical assessment conducted by phone unless patients follow up are&#xD;
             part of the regular clinical visits.&#xD;
&#xD;
        Exclusion Criteria: Any of the following criteria will exclude the subject from the study.&#xD;
&#xD;
          1. Subjects requiring emergent surgery (within 2 hours of presentation) to prevent a&#xD;
             life-threatening situation or death such as those with a perforated colon,&#xD;
             metabolically significant complete bowel obstruction or massive GI bleeding will be&#xD;
             excluded. Subjects who do not require emergent surgery, such as those with occult&#xD;
             bleeding or early or partial bowel obstruction will be permitted to enter.&#xD;
&#xD;
          2. Subjects with any history of Crohn's disease, chronic ulcerative colitis, or familial&#xD;
             polyposis.&#xD;
&#xD;
          3. Discovery of distant metastases intra-operatively.&#xD;
&#xD;
          4. Subjects with history of another malignancy over the last three years (except for&#xD;
             completely resected cervical, skin cancers or in-situ cancers - see Appendix B for a&#xD;
             list of exempt cancers).&#xD;
&#xD;
          5. Pregnant and/or lactating women. Potentially childbearing subjects (pre-menopausal&#xD;
             women) should undergo a pregnancy test within 7 days prior to surgery and after&#xD;
             signing consent. Subjects found to be pregnant will be ineligible and withdrawn from&#xD;
             the study.&#xD;
&#xD;
          6. Subjects should not be participating in another research protocol at the time of&#xD;
             enrollment. Participation during follow-up is acceptable.&#xD;
&#xD;
          7. Systemic chemotherapy for node negative colon cancer.&#xD;
&#xD;
          8. Complete polypectomy by endoscopy&#xD;
&#xD;
          9. Less than 12 lymph nodes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton J. Bilchik, MD, PhD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Wayne Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

